CAPLIN POINT LABORATORIES LTD

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017 UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2011

		Unaud		Unaudited		Audited Year ended
	Particulars		Three months ended		Year ended	
		Jun 30,		Jun 30,		June 30,
		2011	2010	2011	2010	2010
				(Rs in lakhs)		-
1	Income					
	a. Sales/ income from operations	2,762.47	1,348.99	8,113.34	6,071.06	6,070.71
	b. Share of profits in LLP	43.04		282.34		
	c. Total	2,805.51	1,348.99	8,395.68	6,071.06	6,070.71
2	Expenditure					
	a. (Increase)/decrease in stock in trade and work in progress	216.45	(24.52)	(47.71)	128.74	128.74
	b. Consumption of raw materials	572.79/	535,28	2,330.72	2,054.28	2,054.34
	c. Purchase of traded goods	1,506.37	550.15	4,079.63	2,647.19	2,647.19
	d. Excise Duty paid	0.94	0.00	1.46	1.52	1.52
	e. Employees cost	112.37	80.75	405.25	268.73	269.34
	f. Depreciation	26.11	23.74	110.92	92.28	92.47
	g. Amortisation of Goodwill	29.20	29.20	116.80	116.80	116.80
	h. Other Expenditure	195.40	126.65	619.72	486.92	488.92
	i. Total	2,659.63	1,321.25	7,616.79	5,796.46	5,799.32
3	Profit(+)/Loss(-) from Operations before other income and interest (1-2)	145.88	27.74	778.89	274.59	271.39
4	Other Income	44.42	56.83	157.50	176.80	176.81
5	Profit(+)/Loss(-) before interest (3+4)	190.30	84.57	936.39	451.39	448.20
6	Interest Expenses	(30.03)	(21.95)	(104.88)	(83.32)	(83.36
7	Profit(+)/Loss(-) from Ordinary Activities before tax (5-6)	160.27	62.62	831.51	368.07	364.84
8	Provision for Taxation	(36.00)	(19.50)	(138.00)	(30.85)	(31.35
	Provision for Taxation - earlier years	- /	-	1.59	-	
	Deferred Tax Provision	(6.98)	(4.69)	(46.01)	(2.52)	(0.31
9	Net Profit(+)/Loss(-) from Ordinary Activities after tax (7-8)	117.29	38.43	649.09	334.70	333.18
10	Extraordinary Item (net of tax expense)					
11	Net Profit(+)/Loss(-) for the period (9-10)	117.29	38.43	649.09	334.70	333.18
12	Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous	- 1	-	-	S-4	659.17
	accounting year					
14	Earnings/(Loss) Per Share (EPS)					
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	0.78	0.25	4.30	2.22	2.21
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	0.78	0.25	4.30	2.22	2.21
15	Public Shareholding					
	- Number of Shares	5,436,567	5,490,967	5,436,567	5,490,967	5,490,967
	- Percentage of Shareholding	35.98%	36.34%	35.98%	36.34%	
16	Promoters and promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and					
	promoter group)	-	-	-	-	1-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of Shares	9,673,433	9,619,033	9,673,433	9,619,033	9,619,033
	- Percentage of shares (as a % of the total shareholding of promoter and					
	promoter group)	100%	100%	100%	100%	1009
	- Percentage of shares (as a % of the total share capital of the company)	64.02%				
	The second secon	04.02/0	50.0070	57.02/0	30.007	00.00

Notes:

- 1) The Company operates in one segment only.
- 2) Amortisation of Goodwill, which has arisen out of Amalgamation of May India Laboratories P Ltd with this company with effect from 1st April 2006, is being written off over a period of 5 years.
- 3) The above standalone unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30th July 2011.
- 4) The statuory auditors have carried out a limited review of the results for the quarter ended 30th June 2011.
- 5) No investor complaints were pending at the beginning and end of the quarter. 19 complaints were received by the Company during the quarter ended 30th June 2011 and the same were resolved.
- 6) The net profit of the current quarter includes share of profit from Argus Salud Pharma LLP, in which controlling interest is held by the Company.
- 7) Prior year / period figures are regrouped / rearranged wherever necessary.

Place*: Chennai Dated: 30.07.2011 M. Jayapal
Managing Director

CAPLIN POINT LABORATORIES LTD

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017 UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2011

Three months ended Jun 30, 2011 (Rs in lak 2,797.33 118.46 691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30) (0.00)	Year ended Jun 30, 2011 ths) 8,176.77 49.98] 2,537.42 3,606.48 1.46 414.67 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88) 818.27
Jun 30, 2011 (Rs in lak 2,797.33 118.46 691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	Jun 30, 2011 (hs) 8,176.77 (49.98) 2,537.42 3,606.48 1.46, 414.67 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88)
(Rs in lak 2,797.33 118.46 691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	(49.98) 2,537.42 3,606.48 1.46, 414.67, 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88)
2,797.33 118.46 691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	8,176.77 (49.98) 2,537.42 3,606.48 1.46, 414.67, 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88)
691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	2,537.42 3,606.48 1.46, 414.67, 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88)
691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	2,537.42 3,606.48 1.46, 414.67, 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88)
691.87 1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	2,537.42 3,606.48 1.46, 414.67, 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88)
1,343.76 0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	3,606,48 1.46 414,67 115,57 116,80 668,70 7,411,12 765,65 157,50 923,15
0.94 113.71 28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	1.46 414.67 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88
28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	414.67. 115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88
28.04 29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	115.57 116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88
29.20 213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	116.80 668.70 7,411.12 765.65 157.50 923.15 (104.88
213.62 2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	668.70 7,411.12 765.65 157.50 923.15 (104.88
2,539.60 257.73 44.43 302.16 (30.03) 272.13 (45.30)	7,411.12 765.65 157.50 923.15 (104.88
257.73 44.43 302.16 (30.03) 272.13 (45.30)	765.65 157.50 923.15 (104.88)
44.43 302.16 (30.03) 272.13 (45.30)	157.50 923.15 (104.88
302.16 (30.03) 272.13 (45.30)	923.15 (104.88
(30.03) 272.13 (45.30)	(104.88
272.13 / (45.30)	
(45.30)	818.27
1	
(0.00)	(147.30
	1.59
(6.98)	(46.01
219.85	626.55
219.85	626.55
(0.43)	(2.85
219.42	623.70
1,511.00	1,511.00
-	-
1.45	4.13
1.45	4.13
5,436,567	5,436,567
35.98%	35.989
Nil	Nil
-	
-	-
9,673,433	9,673,433
7,070,400	7,070,400
100%	100°
	64.029
	54.02
	5,436,567 35,98% Nii

Notes:

- 1) The Company operates in one segment only.
- 2) Amortisation of Goodwill, which has arisen out of Amalgamation of May India Laboratories P Ltd with this company with effect from 1st April 2006, is being written off over a period of 5 years.
- 3) The above consolidated unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30th July 2011.
- 4) The statuory auditors have carried out a limited review of the results for the quarter ended 30th June 2011.
- 5) The Consolidated financial results include the financial results of Argus Salud Pharma LLP (with effect from 1st Jan 11), in which the controlling interest is held by the Company.
- 6) The consolidated financial statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial statements" and Accounting Standard 23 "Accounting for Investments in Associates in Consolidated Financial statements".
- 7) No investor complaints were pending at the beginning and end of the quarter. 19 complaints were received by the Company during the quarter ended 30th June 2011 and the same were resolved.

Place: Chennai Dated: 30.07.2011 M. Jayapal
Managing Director